A Comparative Registry of the PROmus, ENdeavor and CYpher Drug Eluting Coronary Stent Systems for the Treatment of Coronary Lesions.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 24 Oct 2011
At a glance
- Drugs Everolimus; Sirolimus; Zotarolimus
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms PROENCY
- Sponsors Boston Scientific Corporation
- 24 Oct 2011 Actual patient number added 1934 according to ClinicalTrials.gov.
- 03 Jul 2009 New source identified and integrated (ClinicalTrials.gov; NCT00930878)
- 03 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov